Astrana Health AI Stock Analysis
Want to see ASTH full AI Analyst Report?
Astrana Health (ASTH) AI Stock Analysis
Astrana Health
(NASDAQ:ASTH)
ASTH scores 60 mainly due to strong financial scale-up and improving leverage, supported by a positive earnings call (record results, maintained guidance, and continued deleveraging). The score is held back by meaningful margin compression and weakening free-cash-flow growth, plus weak technical positioning with the stock trading below key moving averages and a sub-40 RSI. Valuation is moderately unfavorable with a ~32 P/E and no dividend yield provided.
Astrana Health (ASTH) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.42B
- Dividend Yield
- ―
- Average Volume (3M)
- 376.53K
- Price to Earnings (P/E)
- 26.6
- Beta (1Y)
- 1.15
- Revenue Growth
- 35.05%
- EPS Growth
- 463.11%
- Country
- US
- Employees
- 3,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Astrana Health Business Overview & Revenue Model
Company Description
Astrana Health, Inc., which rebranded from Apollo Medical Holdings, Inc. in February 2024, is a healthcare management firm based in Alhambra, California, founded in 1985. This company delivers medical services throughout the United States, operating...
How the Company Makes Money
Astrana Health makes money primarily by participating in and supporting value-based healthcare arrangements in which it is financially tied to the total cost and quality of care for defined patient populations. Key revenue and earnings drivers genera...
Astrana Health Earnings Call Summary
The call was strongly positive overall, supported by record revenue and adjusted EBITDA, organic EBITDA growth, strong free cash flow, significant debt reduction, favorable Medicare and Texas performance, Prospect integration progress, and multiple growth initiatives. Management also maintained its full-year outlook and reiterated at least mid-teens medium-term adjusted EBITDA growth. The principal challenges were Medicaid membership attrition and medical cost pressure, expected fourth-quarter seasonality, ACO program transition considerations, the previously disclosed material weakness, and the ongoing cybersecurity investigation. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Astrana is maintaining the midpoint of its full year outlook and now expects revenue of $3.9 billion to $4 billion, adjusted EBITDA of $261 million to $274 million, and free cash flow of $107.5 million to $130 million; fourth-quarter revenue is expected between $939 million and $1.04 billion and adjusted EBITDA between $48.5 million and $61.5 million. The company expects full year G&A to remain around approximately 6.2% of revenue, overall medical cost trend to remain around the approximately 5.2% assumption embedded in full year guidance, and to approach 2x net leverage by year end. It expects at least mid teens annual adjusted EBITDA growth over the medium term, approximately 82% of capitation revenue under full risk arrangements by year end, 10 to 15% decline in Medicaid membership in 2027, Medicare Advantage margins to remain stable into 2027, weighted average paid star rating to improve modestly in 2027 versus 2026 and remain relatively stable in 2028, and at least mid to high teens membership growth in its ACO programs going into 2027.
Astrana Health Financial Statement Overview
Summary
Top-line growth is exceptionally strong (TTM revenue growth 175.8%), and the balance sheet appears improved with low leverage (debt-to-equity 0.13). Offsetting that, profitability has compressed sharply (gross margin down to 7.0% TTM; net margin 1.4%), and free cash flow is positive but weakening (TTM FCF growth -37.3%) with thin cash conversion.
Income Statement
62PositiveBalance Sheet
68PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.91B | 3.18B | 2.03B | 1.39B | 1.14B | 773.91M |
| Gross Profit | 396.48M | 295.78M | 271.39M | 214.96M | 199.48M | 177.77M |
| EBITDA | 214.34M | 135.28M | 141.84M | 123.69M | 112.08M | 100.66M |
| Net Income | 53.13M | 22.49M | 43.15M | 60.72M | 45.17M | 68.92M |
Balance Sheet | ||||||
| Total Assets | 2.34B | 2.22B | 1.35B | 933.36M | 966.21M | 867.36M |
| Cash, Cash Equivalents and Short-Term Investments | 396.23M | 429.47M | 290.83M | 296.31M | 293.59M | 286.51M |
| Total Debt | 977.38M | 1.08B | 471.84M | 321.01M | 229.36M | 200.98M |
| Total Liabilities | 1.71B | 1.66B | 840.73M | 522.59M | 407.67M | 356.72M |
| Stockholders Equity | 856.62M | 779.29M | 712.72M | 614.22M | 542.56M | 448.17M |
Cash Flow | ||||||
| Free Cash Flow | 163.47M | 104.49M | 44.17M | 39.70M | 59.19M | 51.11M |
| Operating Cash Flow | 182.25M | 114.60M | 52.20M | 68.23M | 82.13M | 70.33M |
| Investing Cash Flow | -18.77M | -539.00M | -192.40M | -65.52M | -7.11M | 16.54M |
| Financing Cash Flow | -177.36M | 569.35M | 135.15M | 3.42M | -20.09M | -47.75M |
Astrana Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASTH, the sentiment is Negative. The current price of 28.90 is below the 20-day moving average (MA) of 34.69, below the 50-day MA of 35.82, and below the 200-day MA of 34.48, indicating a bearish trend. The MACD of -1.80 indicates Positive momentum. The RSI at 28.90 is Positive, neither overbought nor oversold. The STOCH value of 7.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASTH.
Astrana Health Risk Analysis
Astrana Health disclosed 78 risk factors in its most recent earnings report. Astrana Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAstrana Health Peers Comparison
Overall Rating
NUTX72Outperform
AGL65Neutral
AVAH65Neutral
INNV62Neutral
ASTH60Neutral
PIII49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | $1.11B | 6.80 | 43.76% | ― | -18.82% | 17.73% | |
| 65Neutral | $1.50B | -13.66 | -51.94% | ― | 2.02% | 66.99% | |
| 65Neutral | $2.34B | 7.28 | 115.53% | ― | 16.84% | 280.13% | |
| 62Neutral | $1.22B | 150.25 | 3.68% | ― | 15.11% | ― | |
| 60Neutral | $1.42B | 26.55 | 6.51% | ― | 35.05% | 463.11% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | $13.50M | -0.08 | 171.75% | ― | 7.54% | 42.43% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ASTH | Astrana Health Inc. | 28.90 | 6.30 | 27.88% | |
| NUTX | Clinigence Holdings Inc | 162.64 | 25.43 | 18.53% | |
| INNV | Innovage Holding Corp. | 9.16 | 3.84 | 72.18% | |
| AGL | Agilon Health Inc | 90.24 | 74.21 | 462.94% | |
| AVAH | Aveanna Healthcare Holdings Inc | 11.01 | 1.97 | 21.79% | |
| PIII | P3 Health Partners Inc. | 1.69 | -4.25 | -71.55% |
Astrana Health Corporate Events
Astrana Health Reports Strong Third-Quarter Revenue and Earnings Growth
PositiveAstrana Health is a physician-centric, technology-enabled healthcare company that combines proprietary technology, aligned physician partnerships and integrated care delivery to help providers deliver accessible, high-quality, high-value care. On Nov...
Astrana Health Showcases AI-Driven Value-Based Care Strategy
PositiveOn September 23, 2026, Astrana Health, Inc. updated a corporate presentation it plans to use at investor conferences and meetings, formally furnishing the materials via a regulatory filing without treating them as filed financial disclosures. The pre...
Astrana Health Updates Investor Presentation, Highlights Risk Model
PositiveOn September 15, 2026, Astrana Health updated its corporate investor presentation for use at conferences and meetings, outlining its delegated risk and financial model as an alternative to traditional fee-for-service and value-based care structures....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
